Novartis leukemia drug wins FDA priority review
Novartis's investigational drug PKC 412 won U.S. Food and Drug Administration priority review, the Swiss drugmaker said on Monday, keeping up momentum after the prospective treatment for a fast-growing form of leukemia garnered breakthrough therapy status this year.

The FDA's fast-track designation reduces the review to six months for the medicine, also known as midostaurin, being tested against newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and advanced systemic mastocytosis.

Analysts think the drug if approved could generate peak annual sales in the hundreds of millions of dollars by 2020....

http://www.reuters.com/article/us-novartis-aml-idUSKBN1390PK
Like
Comment
Share